MedTech Investment

In the previous article, I wrote about the moment optionality begins to narrow in MedTech scale-ups. The natural question for boards is what determines whether that shift is recognised early, or only noticed once timelines begin to stretch. Across portfolios, the answer is rarely capital, rarely technology, and it is almost never effort. The hidden…